A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Control of hepatitis B virus (HBV) infection can be difficult in HIV infected people who have
taken the antiviral lamivudine (3TC). These people may have HBV that has become resistant to
3TC. Adefovir dipivoxil (ADV) has shown promising anti-HBV activity in clinical trials;
tenofovir disoproxil fumarate (TDF) is used to treat HIV and may also be effective against
HBV. The purpose of this study is to find out if adding ADV or TDF to a highly active
antiretroviral therapy (HAART) regimen that includes 3TC has an effect on HBV infection in
patients coinfected with HIV and HBV. The tolerability and safety of these drugs will be
examined.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)